COPILOTNCT07469501
Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation
StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
At risk: Primary completion moved at least 1 year 1 month later.
See at-risk trials from University of California, San Francisco
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from May 2027 to Jul 2028 Show 4 more changesShow less
- Start date: Jun 2026 to Nov 2026
- Eligibility criteria expanded, about 12 words
- Secondary endpoints: 16 to 1
- Publications: details revised at 2 of 2 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Continuous retention in outpatient buprenorphine treatment by day 90
Timeframe: 90 days
Self-reported protocol satisfaction at day 7
Timeframe: 7 days
Secondary (1)
Successful buprenorphine initiation within first 7 days
Arms and interventions
Low-dose initiation (LDI)Active comparator
Participants start 0.5mg sublingual buprenorphine (Subutex) and gradually increase by 0.5-1.0mg daily for 7 days
Direct-to-inject (DTI)Experimental
Participants receive 8-32mg long-acting injectable buprenorphine (Brixadi or Sublocade) on day 1, followed by monthly injections as discussed with the provider
Drugs: Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Sites
1 site in 1 country
- San Francisco Outpatient Buprenorphine Induction ClinicSan Francisco, California, United States